Observation on curative effect of decitabine combined with CAG scheme in treatment of myelodysplastic syndrome

Objective To observe the clinical effect of decitabine combined with CAG scheme in the treatment of myelodysplastic syndrome.Methods 73 cases of myelodysplastic syndrome in our hospital from February 2007 to January 2012 were chosen and randomly divided into the control group(36cases)and the treatment group(37cases).The control group was treated with the CAG regimen,while the treatment group was given the CAG scheme combined with decitabine treatment.The changes of vascular endothelial growth factor(VEGF)before treatment and after treatment,total effective rate,survival time and adverse reactions were compared between the two groups.ResultsThe VEGF levels on 1,3,7,14 dafter treatment in the two group were all significantly lower than those before therapy(P0.05),moreover the decrease in the treatment group was more significant than the control group,the difference was statistically significant(P0.05);the total effective rates of the treatment group and the control group were75.6% and 61.1% respectively,the treatment group was higher than the control group with statistical difference(P0.05);the overall survival time and disease-free survival time in the treatment group were significantly better than those in the control group,the differences were statistically significant(P0.05);the incidence rate of adverse reactions in the treatment group was 67.2%,which was significantly lower than 77.8%in the control group,the differences were statistically significant(P0.05).Conclusion Decitabine combined with CAG scheme in treating myelodysplastic syndrome has long survival time,obvious effect and is worthy of promotion.